LivaNova Sleep Apnea Device Could Drive Growth From 2026, Needham Says

MT Newswires Live

Sep 04

LivaNova (LIVN) could see growth contributions starting in 2026 from its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea, Needham said in a Wednesday note.

The firm said LivaNova submitted the device for premarket approval and estimated potential FDA clearance in the first half of 2026. In its base-case scenario, Needham projects aura6000 could add 2.2% to annual revenue growth and 4.7% to annual earnings per share growth from 2026 to 2029.

The brokerage highlighted results from the osprey trial, which showed a 65% responder rate and a 68% reduction in apnea-hypopnea index at 12 months. The firm said LivaNova expects to launch the device after obtaining MRI compatibility approval, likely in late 2026.

The device could capture market share from Inspire Medical (INSP), with advantages including longer battery life, the ability to treat patients with complete concentric collapse, and no requirement for a drug-induced sleep endoscopy procedure.

Needham has a buy rating and a $64 price target on LivaNova.

Shares of LivaNova were down 1.4% in recent trading.

Price: 56.10, Change: -0.82, Percent Change: -1.44

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2564169023"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564169023\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564169023?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 03:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564169023","market":"us","top_or_hot":-1,"title":"LivaNova Sleep Apnea Device Could Drive Growth From 2026, Needham Says","media":"MT Newswires Live","content":"<html><body><p> LivaNova (LIVN) could see growth contributions starting in 2026 from its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea, Needham said in a Wednesday note.</p><p>The firm said LivaNova submitted the device for premarket approval and estimated potential FDA clearance in the first half of 2026. In its base-case scenario, Needham projects aura6000 could add 2.2% to annual revenue growth and 4.7% to annual earnings per share growth from 2026 to 2029.</p><p>The brokerage highlighted results from the osprey trial, which showed a 65% responder rate and a 68% reduction in apnea-hypopnea index at 12 months. The firm said LivaNova expects to launch the device after obtaining MRI compatibility approval, likely in late 2026.</p><p>The device could capture market share from Inspire Medical (INSP), with advantages including longer battery life, the ability to treat patients with complete concentric collapse, and no requirement for a drug-induced sleep endoscopy procedure.</p><p>Needham has a buy rating and a $64 price target on LivaNova.</p><p>Shares of LivaNova were down 1.4% in recent trading.</p><p>Price: 56.10, Change: -0.82, Percent Change: -1.44</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LivaNova Sleep Apnea Device Could Drive Growth From 2026, Needham Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivaNova Sleep Apnea Device Could Drive Growth From 2026, Needham Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-04 03:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> LivaNova (LIVN) could see growth contributions starting in 2026 from its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea, Needham said in a Wednesday note.</p><p>The firm said LivaNova submitted the device for premarket approval and estimated potential FDA clearance in the first half of 2026. In its base-case scenario, Needham projects aura6000 could add 2.2% to annual revenue growth and 4.7% to annual earnings per share growth from 2026 to 2029.</p><p>The brokerage highlighted results from the osprey trial, which showed a 65% responder rate and a 68% reduction in apnea-hypopnea index at 12 months. The firm said LivaNova expects to launch the device after obtaining MRI compatibility approval, likely in late 2026.</p><p>The device could capture market share from Inspire Medical (INSP), with advantages including longer battery life, the ability to treat patients with complete concentric collapse, and no requirement for a drug-induced sleep endoscopy procedure.</p><p>Needham has a buy rating and a $64 price target on LivaNova.</p><p>Shares of LivaNova were down 1.4% in recent trading.</p><p>Price: 56.10, Change: -0.82, Percent Change: -1.44</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2564169023","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564169023","pubTimestamp":1756928654,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"LivaNova  could see growth contributions starting in 2026 from its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea, Needham said in a Wednesday note.The firm said LivaNova submitted the device for premarket approval and estimated potential FDA clearance in the first half of 2026. In its base-case scenario, Needham projects aura6000 could add 2.2% to annual revenue growth and 4.7% to annual earnings per share growth from 2026 to 2029.The brokerage highlighted results from the osprey trial, which showed a 65% responder rate and a 68% reduction in apnea-hypopnea index at 12 months. The firm said LivaNova expects to launch the device after obtaining MRI compatibility approval, likely in late 2026.The device could capture market share from Inspire Medical , with advantages including longer battery life, the ability to treat patients with complete concentric collapse, and no requirement for a drug-induced sleep endoscopy procedure.Needham has a buy rating and a $64 ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","INSP":"Inspire Medical Systems","BK4167":"医疗保健技术","LIVN":"LivaNova PLC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC"},"translate_title":"Needham表示，LivaNova睡眠呼吸暂停设备可能会从2026年起推动增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSP":0.9,"LIVN":0.9},"content_text":"LivaNova (LIVN) could see growth contributions starting in 2026 from its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea, Needham said in a Wednesday note.The firm said LivaNova submitted the device for premarket approval and estimated potential FDA clearance in the first half of 2026. In its base-case scenario, Needham projects aura6000 could add 2.2% to annual revenue growth and 4.7% to annual earnings per share growth from 2026 to 2029.The brokerage highlighted results from the osprey trial, which showed a 65% responder rate and a 68% reduction in apnea-hypopnea index at 12 months. The firm said LivaNova expects to launch the device after obtaining MRI compatibility approval, likely in late 2026.The device could capture market share from Inspire Medical (INSP), with advantages including longer battery life, the ability to treat patients with complete concentric collapse, and no requirement for a drug-induced sleep endoscopy procedure.Needham has a buy rating and a $64 price target on LivaNova.Shares of LivaNova were down 1.4% in recent trading.Price: 56.10, Change: -0.82, Percent Change: -1.44","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}